Siegmann K C, Müller K-T, Vogel U, Krauss K, Claussen C D
Abteilung für Diagnostische und Interventionelle Radiologie, Universitätsklinikum Tübingen.
Rofo. 2010 Jun;182(6):493-500. doi: 10.1055/s-0028-1109883. Epub 2009 Dec 1.
Analysis of enhancement characteristics and T 2 signal intensity (SI) of breast cancers and normal breast parenchyma on MR imaging (MRI) before and after neoadjuvant treatment (NT) to improve the assessment of therapy response.
Retrospective data analysis of 43 consecutive patients (mean age 49.9 years) with invasive breast cancers (T2 /T3) who received NT. Evaluation of breast MRI before and after NT with assessment of therapy response according to RECIST criteria as well as calculation of the maximum initial enhancement (Enh (max)), delayed enhancement (Enh (post)) and T 2 SI by ROI analyses of breast cancers and breast parenchyma. Comparison of therapy response and enhancement characteristics.
Therapy response on MRI: 16.3 % (n = 7) complete remission (CR (MRT)), 53.5 % (n = 23) partial remission (PR (MRT)), 27.9 % (n = 12) stable disease (SD (MRT)) und 2.3 % (n = 1) progressive disease (PD (MRT)). Breast cancers showed a significant decrease in Enh (max) and T 2 SI as well as a significant increase in Enh (post) after NT (p < 0.01). Not any SI parameter of normal breast parenchyma showed a significant change after NT (p > 0.05). All cases with CR (MRT) had wash out or plateau shape of the SI time curve before NT and showed continuous enhancement thereafter.
Breast MRI shows significant changes in enhancement characteristics and T 2 SI of breast cancers after NT, whereas normal breast parenchyma remains unchanged. SI data could possibly help to improve the assessment of therapy response by MRI. Prospective trials with larger study cohorts and MRI monitoring during NT are necessary to validate these results.
分析新辅助治疗(NT)前后乳腺癌及正常乳腺实质在磁共振成像(MRI)上的强化特征和T2信号强度(SI),以改善对治疗反应的评估。
对43例连续接受NT的浸润性乳腺癌(T2/T3)患者(平均年龄49.9岁)进行回顾性数据分析。根据RECIST标准评估NT前后的乳腺MRI,并通过对乳腺癌和乳腺实质的感兴趣区(ROI)分析计算最大初始强化(Enh(max))、延迟强化(Enh(post))和T2 SI。比较治疗反应和强化特征。
MRI上的治疗反应:16.3%(n = 7)完全缓解(CR(MRT)),53.5%(n = 23)部分缓解(PR(MRT)),27.9%(n = 12)疾病稳定(SD(MRT)),2.3%(n = 1)疾病进展(PD(MRT))。NT后乳腺癌的Enh(max)和T2 SI显著降低,Enh(post)显著增加(p < 0.01)。NT后正常乳腺实质的任何SI参数均未显示出显著变化(p > 0.05)。所有CR(MRT)病例在NT前SI时间曲线呈廓清或平台型,此后呈持续强化。
NT后乳腺MRI显示乳腺癌的强化特征和T2 SI有显著变化,而正常乳腺实质保持不变。SI数据可能有助于通过MRI改善对治疗反应的评估。需要进行更大样本队列的前瞻性试验以及NT期间的MRI监测来验证这些结果。